Flossbach Von Storch SE Purchases 17,096 Shares of Becton, Dickinson and Company $BDX

Flossbach Von Storch SE increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 211,226 shares of the medical instruments supplier’s stock after buying an additional 17,096 shares during the period. Flossbach Von Storch SE owned about 0.07% of Becton, Dickinson and Company worth $36,384,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. First Eagle Investment Management LLC raised its holdings in shares of Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock valued at $1,513,421,000 after purchasing an additional 3,268,478 shares in the last quarter. GQG Partners LLC bought a new position in Becton, Dickinson and Company in the first quarter worth approximately $689,833,000. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 4.7% during the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier’s stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the period. Nuveen LLC bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at $211,097,000. Finally, Kingstone Capital Partners Texas LLC purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at $155,080,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 1,249 shares of company stock valued at $231,358 in the last 90 days. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $177.88 on Friday. The company has a 50 day moving average price of $186.77 and a 200 day moving average price of $182.30. The firm has a market capitalization of $50.99 billion, a P/E ratio of 31.99, a PEG ratio of 1.42 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.32 billion for the quarter. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is currently 71.36%.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of analyst reports. Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Piper Sandler reduced their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday. Finally, Royal Bank Of Canada lowered their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating for the company in a research note on Friday. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $203.27.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.